Over-the-counter medications for heartburn, reflux and morning sickness are at the centre of a class action investigation over alleged links to stomach cancer and kidney damage that could involve an estimated 100,000 Australians.

Patients who have used proton pump inhibitors (PPIs) to treat digestive issues, and subsequently developed gastric cancer or kidney damage, may be entitled to compensation should the investigation proceed to litigation. 

Luke Grant spoke with Special Counsel Lorne Franks, of Shine Lawyers who are investigating the Class Action, to discuss which specific medications are being investigated, what the research says about the links between PPis with kidney damage and stomach cancers and who is eligible to submit to be part of the Class Action.